Combination improves endocrine response after CDK4/6 inhibition in ER-positive, HER2-negative advanced breast cancer
A little does not go a long way to treating cancer: updated ESMO study results cause concern about stalling progress in access to medicines
Final analysis reports a lack of overall survival benefit with datopotamab deruxtecan in HR+/HER2– breast cancer compared to chemotherapy